Hosted on MSN2d
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...
Business Wire2d
Kenai Therapeutics Establishes Research Facility at Lilly Gateway Labs
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-s ...
Wall Street Journal3d
Summit Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
ascopubs.org4d
De-Escalation Strategies With Immune Checkpoint Blockers in Non–Small Cell Lung Cancer: Do We Already Have Enough Evidence?
Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...